Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF Mutant Metastatic Melanoma”

48 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 48 results

Testing effectiveness (Phase 2)Ended earlyNCT01777776
What this trial is testing

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Who this might be right for
Locally Advanced Metastatic BRAF Mutant Melanoma
Array BioPharma 28
Early research (Phase 1)WithdrawnNCT02915666
What this trial is testing

A Clinical Trial of Patients With Melanoma

Who this might be right for
Melanoma
University of Texas Southwestern Medical Center
Early research (Phase 1)Ended earlyNCT01940809
What this trial is testing

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Melanoma+5 more
National Cancer Institute (NCI) 15
Large-scale testing (Phase 3)Study completedNCT01909453
What this trial is testing

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

Who this might be right for
Melanoma
Pfizer 921
Early research (Phase 1)Study completedNCT01436656
What this trial is testing

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Who this might be right for
Melanoma and Metastatic Colorectal Cancer
Pfizer 107
Testing effectiveness (Phase 2)Ended earlyNCT01495988
What this trial is testing

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Who this might be right for
MelanomaMetastatic Melanoma
Melanoma Research Foundation Breakthrough Consortium 10
Testing effectiveness (Phase 2)Study completedNCT01153763
What this trial is testing

GSK2118436 in BRAF Mutant Metastatic Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline 92
Testing effectiveness (Phase 2)Active Not RecruitingNCT01989585
What this trial is testing

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Malignant Solid Neoplasm+2 more
National Cancer Institute (NCI) 75
Early research (Phase 1)Study completedNCT03415126
What this trial is testing

ASN007 in Patients With Advanced Solid Tumors

Who this might be right for
CancerMalignancyNeoplasia+16 more
Asana BioSciences 49
Large-scale testing (Phase 3)Study completedNCT01227889
What this trial is testing

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Who this might be right for
Cancer
GlaxoSmithKline 251
Early research (Phase 1)Ended earlyNCT03878719
What this trial is testing

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Who this might be right for
Melanoma
Pfizer 1
Testing effectiveness (Phase 2)Study completedNCT01266967
What this trial is testing

GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain

Who this might be right for
Melanoma and Brain Metastases
GlaxoSmithKline 172
Early research (Phase 1)Looking for participantsNCT04903119
What this trial is testing

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Who this might be right for
Metastatic MelanomaBRAF Gene Mutation
Rina Plattner 30
Testing effectiveness (Phase 2)Study completedNCT03898908
What this trial is testing

Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain

Who this might be right for
Metastatic MelanomaBrain Metastases
Grupo Español Multidisciplinar de Melanoma 48
Testing effectiveness (Phase 2)Study completedNCT01072175
What this trial is testing

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Who this might be right for
Cancer
Novartis Pharmaceuticals 430
Testing effectiveness (Phase 2)Looking for participantsNCT04511013
What this trial is testing

Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Who this might be right for
Acral Lentiginous MelanomaClinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Cutaneous Melanoma+4 more
SWOG Cancer Research Network 112
Early research (Phase 1)Ended earlyNCT02974725
What this trial is testing

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Who this might be right for
Non-Small Cell Lung CancerMelanoma
Novartis Pharmaceuticals 241
Early research (Phase 1)Ended earlyNCT02097225
What this trial is testing

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Malignant Solid Neoplasm+7 more
National Cancer Institute (NCI) 22
Large-scale testing (Phase 3)Study completedNCT01245062
What this trial is testing

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline 322
Early research (Phase 1)Study completedNCT03864042
What this trial is testing

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Melanoma
Pfizer 56
Load More Results